Antibiotice Iasi Reports RON74M Net Profit For H1/2024, Up 20% YoY

08.14.2024 By Ecaterina Craciun

Romanian-owned drug manufacturer Antibiotice Iasi (stock symbol: ATB) ended the first half of 2024 with net profit of RON74 million, up 20% on the year, while its revenue rose by 8% to RON380 million, as per the company's half-yearly financial report published at the Bucharest Stock Exchange on Wednesday (August 14).

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
Antibiotice Iasi
, earnings